Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

Author(s):

Pedro Barata, MD, MSc,Martin H. Voss, MD

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.

EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

Now Viewing

EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

EP: 5.Exciting Data and Trials in Progress from ASCO 2024

EP: 6.Ongoing RCC Clinical Trials that may Impact Practice

EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data

EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC

EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

EP: 12.The Role of Chemotherapy in nccRCC Treatment

EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

EP: 14.Final Thoughts/Looking Forward

Please briefly discuss the recent data from the CheckMate 214 trial evaluating nivo + ipi for 1L treatment of advanced RCC.
1. 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (Tannir et al., ASCO GU 2024 Abstract 363)
2. What insights do the recent HRQoL data provide? (Cella et al., Oncologist Jan 2024)
Please comment on the role of doublet regimens in the 1L setting for advanced RCC and their recent data updates.
1. CheckMate 9ER nivo + cabo
2. 55-month follow up (Bourlon et al., ASCO GU 2024 Abstract 362)
3. HRQoL (Bedke et al., ASCO GU 2024 Abstract 384)
4. Partitioned 4-year OS (Mantia et al., ASCO 2024 Abstract 4507)